Growth Metrics

Gilead Sciences (GILD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $147.0 million.

  • Gilead Sciences' Capital Expenditures rose 425.53% to $147.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.0 million, marking a year-over-year decrease of 1455.16%. This contributed to the annual value of $523.0 million for FY2024, which is 1059.83% down from last year.
  • Per Gilead Sciences' latest filing, its Capital Expenditures stood at $147.0 million for Q3 2025, which was up 425.53% from $107.0 million recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Capital Expenditures ranged from a high of $247.0 million in Q1 2022 and a low of $104.0 million during Q1 2025
  • Over the past 5 years, Gilead Sciences' median Capital Expenditures value was $141.0 million (recorded in 2024), while the average stood at $145.9 million.
  • In the last 5 years, Gilead Sciences' Capital Expenditures surged by 4969.7% in 2022 and then tumbled by 5587.04% in 2023.
  • Gilead Sciences' Capital Expenditures (Quarter) stood at $156.0 million in 2021, then rose by 16.03% to $181.0 million in 2022, then grew by 18.78% to $215.0 million in 2023, then plummeted by 31.63% to $147.0 million in 2024, then changed by 0.0% to $147.0 million in 2025.
  • Its Capital Expenditures was $147.0 million in Q3 2025, compared to $107.0 million in Q2 2025 and $104.0 million in Q1 2025.